| Name | Title | Contact Details |
|---|
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel anti-infective agents to address the threat of antibiotic resistance. The company name, VenatoRx (ven-a-TOR-ex), derives from the latin word “venator”, meaning hunter and “Rx”, the medical symbol for drugs. The pursuit, or “hunt”, for new drugs is the core mission of the company. Located northwest of Philadelphia in Malvern, PA, the company was founded in 2010 by Drs. Burns, Xerri, and Pevear. Since founding, the company has received multiple awards from the NIH, including 5 Small Business Innovative Research (SBIR) grants and an R01 grant. The company has also been awarded a contract from the NIH and funding from the Wellcome Trust to advance the company’s product candidates.
Spectrum Sciences is a California, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sciex helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company`s global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis.
Chroma Medicine is pioneering a new class of epigenetic medicines to revolutionize treatment of genetically driven disease.